These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

504 related articles for article (PubMed ID: 24012083)

  • 1. Psychopharmacologic treatment of psychosis in children and adolescents: efficacy and management.
    Kranzler HN; Cohen SD
    Child Adolesc Psychiatr Clin N Am; 2013 Oct; 22(4):727-44. PubMed ID: 24012083
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Psychopharmacologic Treatment of Schizophrenia in Adolescents and Children.
    Lee ES; Kronsberg H; Findling RL
    Child Adolesc Psychiatr Clin N Am; 2020 Jan; 29(1):183-210. PubMed ID: 31708047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of second-generation antipsychotics in children and adolescents with psychotic and bipolar spectrum disorders: comprehensive review of prospective head-to-head and placebo-controlled comparisons.
    Fraguas D; Correll CU; Merchán-Naranjo J; Rapado-Castro M; Parellada M; Moreno C; Arango C
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):621-45. PubMed ID: 20702068
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Side effects of antipsychotics in the elderly.
    Masand PS
    J Clin Psychiatry; 2000; 61 Suppl 8():43-9; discussion 50-1. PubMed ID: 10811243
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clozapine for treatment-resistant schizophrenia: National Institute of Clinical Excellence (NICE) guidance in the real world.
    Mortimer AM; Singh P; Shepherd CJ; Puthiryackal J
    Clin Schizophr Relat Psychoses; 2010 Apr; 4(1):49-55. PubMed ID: 20643629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clozapine users in Australia: their characteristics and experiences of care based on data from the 2010 National Survey of High Impact Psychosis.
    Siskind DJ; Harris M; Phillipou A; Morgan VA; Waterreus A; Galletly C; Carr VJ; Harvey C; Castle D
    Epidemiol Psychiatr Sci; 2017 Jun; 26(3):325-337. PubMed ID: 27426892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clozapine: more side effects but still the best antipsychotic.
    Kang X; Simpson GM
    J Clin Psychiatry; 2010 Aug; 71(8):982-3. PubMed ID: 20797378
    [No Abstract]   [Full Text] [Related]  

  • 9. Antipsychotics in children and adolescents: increasing use, evidence for efficacy and safety concerns.
    Vitiello B; Correll C; van Zwieten-Boot B; Zuddas A; Parellada M; Arango C
    Eur Neuropsychopharmacol; 2009 Sep; 19(9):629-35. PubMed ID: 19467582
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The risks and benefits of switching patients with schizophrenia or schizoaffective disorder from two to one antipsychotic medication: a randomized controlled trial.
    Constantine RJ; Andel R; McPherson M; Tandon R
    Schizophr Res; 2015 Aug; 166(1-3):194-200. PubMed ID: 26141142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aripiprazole in schizophrenia and schizoaffective disorder: A review.
    Stip E; Tourjman V
    Clin Ther; 2010; 32 Suppl 1():S3-20. PubMed ID: 20152550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New findings on antipsychotic use in children and adolescents with schizophrenia spectrum disorders.
    Ross RG
    Am J Psychiatry; 2008 Nov; 165(11):1369-72. PubMed ID: 18981065
    [No Abstract]   [Full Text] [Related]  

  • 13. Second generation antipsychotics (SGAs) for non-psychotic disorders in children and adolescents: a review of the randomized controlled studies.
    Zuddas A; Zanni R; Usala T
    Eur Neuropsychopharmacol; 2011 Aug; 21(8):600-20. PubMed ID: 21550212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update and recommendations for the use of antipsychotics in early-onset psychoses.
    Bryden KE; Carrey NJ; Kutcher SP
    J Child Adolesc Psychopharmacol; 2001; 11(2):113-30. PubMed ID: 11436951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Off-Label Use of Clozapine in Children and Adolescents-A Literature Review.
    Rachamallu V; Elberson BW; Vutam E; Aligeti M
    Am J Ther; 2019; 26(3):e406-e416. PubMed ID: 31082865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-label second generation antipsychotics for impulse regulation disorders: a review.
    Scheltema Beduin A; de Haan L
    Psychopharmacol Bull; 2010; 43(3):45-81. PubMed ID: 21150846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment pathway and patterns of clozapine prescribing for schizophrenia in New Zealand.
    Wheeler AJ
    Ann Pharmacother; 2008 Jun; 42(6):852-60. PubMed ID: 18477732
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence base for using atypical antipsychotics for psychosis in adolescents.
    Datta SS; Kumar A; Wright SD; Furtado VA; Russell PS
    Schizophr Bull; 2014 Mar; 40(2):252-4. PubMed ID: 24361758
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Weight gain and metabolic risks associated with antipsychotic medications in children and adolescents.
    Maayan L; Correll CU
    J Child Adolesc Psychopharmacol; 2011 Dec; 21(6):517-35. PubMed ID: 22166172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and tolerability of antipsychotic treatment in young patients with schizophrenia.
    Correll CU
    J Clin Psychiatry; 2011 Aug; 72(8):e26. PubMed ID: 21899814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.